DYN Share Price | Dyne Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Dyne Therapeutics, Inc.?

Market Cap: As of Jun 18, Dyne Therapeutics, Inc. has a market capitalization of 1,235.77 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Dyne Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -367.12 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 629.84 million and total assets of 691.23 million.

Q: What does Dyne Therapeutics, Inc. do?

Overview: Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.Financial Snapshot: Most recent Net Profit: -115 Million (Quarterly Results - Mar 2025) Market cap: USD 1,235.77 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -54.88% Price to Book: 1.85Contact Details: Address: 830 Winter Street, WALTHAM MA: 02451 Tel: 1 781 7868230 Fax: 1 781 7868866 Website: https://www.dyne-tx.com/

Q: Is Dyne Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Dyne Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals. The RSI shows no signal on the weekly timeframe but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly, and moving averages indicate a mildly bearish stance on the daily. The KST is bullish weekly but bearish monthly, and the OBV is mildly bearish weekly and mildly bullish monthly. In terms of performance, Dyne Therapeutics has underperformed significantly against the S&P 500 over the longer term, with a year-to-date return of -40.92% compared to the S&P 500's 12.22%, and a one-year return of -59.46% versus 17.14%. This suggests a strong bearish sentiment overall, despite some short-term bullish indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.15 M

Shareholding (Dec 2025)

FII

20.52%

Held by 123 FIIs

DII

Held by 81 DIIs

Promoter

24.68%

How big is Dyne Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Dyne Therapeutics, Inc. has a market capitalization of $1.24 billion, with net sales of $0.00 million and a net profit of -$367.12 million over the latest four quarters. The company reported shareholder's funds of $629.84 million and total assets of $691.23 million as of Dec 24.

View full answer

What does Dyne Therapeutics, Inc. do?

22-Jun-2025

Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for genetically driven diseases, with a market cap of approximately $1.24 billion and a recent net profit of -$115 million. The company is classified as small-cap and operates in the Pharmaceuticals & Biotechnology industry.

View full answer

Who are in the management team of Dyne Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Dyne Therapeutics, Inc. includes Mr. Jason Rhodes as Executive Chairman and Mr. Joshua Brumm as President, CEO, and Director.

View full answer

Is Dyne Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Dyne Therapeutics shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly with a year-to-date return of -40.92%.

View full answer

Compare Dyne Therapeutics, Inc. with Similar Stocks

Entrada Therapeutics, Inc.4D Molecular Therapeutics, Inc.HilleVax, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,994 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-61.26%

Price to Book

4.33

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-112 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-12.44%

6 Months

35.48%

1 Year

47.93%

2 Years

-36.72%

3 Years

59.84%

4 Years

93.19%

5 Years

17.57%

Dyne Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-211.51%

EBIT to Interest (avg)

-251.07

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.33

EV to EBIT

-5.14

EV to EBITDA

-5.16

EV to Capital Employed

565.04

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-11003.50%

ROE (Latest)

-61.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 61 Schemes (58.73%)

Foreign Institutions

Held by 123 Foreign Institutions (20.52%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -25.14% vs -34.38% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-115.60",
          "val2": "-96.10",
          "chgp": "-20.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-112.00",
          "val2": "-89.50",
          "chgp": "-25.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -40.58% vs -34.55% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-466.10",
          "val2": "-341.60",
          "chgp": "-36.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-446.20",
          "val2": "-317.40",
          "chgp": "-40.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-115.60

-96.10

-20.29%

Interest

3.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-112.00

-89.50

-25.14%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -25.14% vs -34.38% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-466.10

-341.60

-36.45%

Interest

6.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-446.20

-317.40

-40.58%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -40.58% vs -34.55% in Dec 2024

All Annual Results

Company CV

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.

Company Coordinates

Company Details

830 Winter Street , WALTHAM MA : 02451

Tel: 1 781 7868230

https://www.dyne-tx.com/

Registrar Details